Department of Dermatology, University Hospital, Medizinische Fakultät Carl Gustav Carus, TU Dresden, Dresden, Germany.
Department of Pediatrics, University Hospital, Medizinische Fakultät Carl Gustav Carus, TU Dresden, Dresden, Germany.
Front Immunol. 2023 Sep 21;14:1253279. doi: 10.3389/fimmu.2023.1253279. eCollection 2023.
Cutaneous lupus erythematosus (CLE), the main manifestation of systemic lupus erythematosus (SLE), is driven by type I interferons (IFNs) and often only partially responds to conventional therapies. Treatment of seven SLE patients with the monoclonal antibody anifrolumab induced fast and sustained remission of previously refractory CLE lesions, beginning within the first weeks of treatment. Decline in CLASI-A score was paralleled by a reduction in IFN score determined by mRNA expression of seven IFN-stimulated genes (ISGs) in blood. These data suggest that a subset of ISGs could be a valuable biomarker in CLE.
皮肤狼疮红斑（CLE）是系统性红斑狼疮（SLE）的主要表现形式，由 I 型干扰素（IFNs）驱动，并且通常仅对常规治疗有部分反应。用单克隆抗体 anifrolumab 治疗 7 名 SLE 患者，可快速和持续缓解以前难治性 CLE 病变，在治疗的第一周内开始起效。CLASI-A 评分下降与通过血液中七个干扰素刺激基因（ISGs）的 mRNA 表达确定的 IFN 评分降低相平行。这些数据表明，ISG 的一个亚群可能是 CLE 的一个有价值的生物标志物。
